IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Companyâ€™s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotechâ€™s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/07/26	$0.005500	-8.33%	29,903
16/07/26	$0.006000	+20.00%	1,144,948
15/07/26	$0.005000	-15.25%	278,333
14/07/26	$0.005900	+18.00%	232,203
13/07/26	$0.005000	-5.21%	162,940

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 23:22:14 17/07/2026 +04			5-day change	1st Jan Change
0.005500 ^USD	-8.33%		+3.77%	-99.10%

04-06	IO Biotech, Inc.(OTCPK:IOBT.Q) dropped from NASDAQ Composite Index	CI
03-31	IO Biotech, Inc. Filed for Bankruptcy	CI

Market Cap	43.81M 38.29M 35.33M 32.56M 61.38M 4.22B 62.74M 422M 166M 2.07B 165M 161M 7.11B	P/E 2023	-0.95x	P/E 2024	-0.63x
Enterprise Value	-14.31M -12.5M -11.54M -10.63M -20.04M -1.38B -20.49M -138M -54.24M -675M -53.73M -52.55M -2.32B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	99.69%	Yield 2023 *	-	Yield 2024	-

04-06	IO Biotech, Inc.(OTCPK:IOBT.Q) dropped from NASDAQ Composite Index	CI
03-31	IO Biotech, Inc. Filed for Bankruptcy	CI
03-31	Io Biotech Inc - files voluntary chapter 7 bankruptcy petition on March 31, 2026 - SEC filing	RE
03-31	IO Biotech, Inc. Terminates Amy Sullivan as Chief Financial Officer on March 31, 2026	CI
03-31	IO Biotech, Inc. Announces Termination of Mai-Britt Zocca as Chief Executive Officer	CI
03-31	IO Biotech, Inc. Announces Management Changes on March 31, 2026	CI
02-17	CNS Pharmaceuticals, Inc. Announces Executive Appointments, Effective March 2, 2026	CI
01-31	Biotech, Inc. Announces Departure of Qasim Ahmad as Chief Medical Officer and Executive Officer, Effective February 15, 2026	CI
01-30	IO Biotech, Inc. Implements Significant Workforce Reduction as Part of Cost-Containment Measures While Exploring Strategic Alternatives	CI
01-26	IO Biotech Shares Fall After Piper Sandler Downgrade	MT
01-26	Piper Sandler Downgrades IO Biotech to Neutral From Overweight, Adjusts Price Target to $0.50 From $3	MT
01-21	Io Biotech announces exploration of strategic alternatives	RE
01-08	Morgan Stanley Downgrades IO Biotech to Underweight, Price Target is $0.36	MT

01-26	IO Biotech Shares Fall After Piper Sandler Downgrade	MT
01-26	Piper Sandler Downgrades IO Biotech to Neutral From Overweight, Adjusts Price Target to $0.50 From $3	MT
01-08	Morgan Stanley Downgrades IO Biotech to Underweight, Price Target is $0.36	MT
30/09/25	IO Biotech Faces Setback as FDA Opposes Cylembio BLA Submission, Morgan Stanley Says	MT
30/09/25	TD Cowen Downgrades IO Biotech to Hold From Buy	MT

IO Biotech, Inc. Stock

Stocks

IOBTQ

US4497781090

Biotechnology & Medical Research

Valuation: IO Biotech, Inc.

Chart: IO Biotech, Inc.

Latest news : IO Biotech, Inc.

Last Transcript: IO Biotech, Inc.

Analysts' recommendations: IO Biotech, Inc.

Press Releases: IO Biotech, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: IO Biotech, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

02-02	IO Biotech Provides Corporate Update	AQ
01-30	IO Biotech Provides Corporate Update	AQ
01-21	IO Biotech Announces Exploration of Strategic Alternatives	AQ
12-16	IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications	AQ
11-26	IO Biotech Announces Participation in Upcoming December Investor Conferences	AQ

1 day	-8.33%
1 week	+3.77%
Current month	-9.84%
1 month	-8.33%
3 months	+7.84%
6 months	-98.90%
Current year	-99.10%

1 week	0		0.01
1 month	0		0.01
Current year	0		0.7
1 year	0		2.79
3 years	0		2.79
5 years	0		17.88
10 years	0		17.88

Manager	Title	Age	Since
Diane McDowell CTO	Chief Tech/Sci/R&D Officer	-	01/10/2021
Devin Smith CMP	Compliance Officer	58	23/01/2023
Maryann Cimino IRC	Investor Relations Contact	-	01/04/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
05/06/25	David Smith	Free	Director	35,144	0.0533%
05/06/25	Helen Collins	Free	Director	35,144	0.0533%
05/06/25	K. Hirth	Free	Chairman	35,144	0.0533%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IO BIOTECH, INC.	-8.33%	+3.77%	-99.73%	-99.70%	396K
LONZA GROUP AG	-1.29%	-3.11%	-0.35%	+2.64%	49.18B
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+386.06%	+588.97%	39.58B
BEONE MEDICINES AG	-1.70%	+4.46%	+5.93%	+61.54%	34.69B
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+28.41%	-8.52%	34.42B
CELLTRION, INC.	+0.06%	+0.34%	+2.38%	+34.47%	27.11B
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	16.21B
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+72.42%	+116.45%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+14.54%	+15.44%	14.05B
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+18.43%	-31.23%	13.02B
Average	-0.78%	+0.45%	+47.56%	+75.56%	24.36B
Weighted average by Cap.	-0.05%	-0.18%	+79.44%	+122.31%

	2023	2024
Net sales	-	-
Net income	-86.08M -75.23M -69.42M -63.99M -121M -8.29B -123M -830M -326M -4.06B -323M -316M -13.98B	-95.49M -83.45M -77M -70.98M -134M -9.2B -137M -920M -362M -4.5B -359M -351M -15.5B
Net Debt	-141M -123M -113M -105M -197M -13.55B -201M -1.36B -533M -6.64B -528M -517M -22.84B	-58.12M -50.79M -46.87M -43.2M -81.42M -5.6B -83.23M -560M -220M -2.74B -218M -213M -9.44B